[
  {
    "ts": "2026-02-06T14:00:05+00:00",
    "headline": "Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
    "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-attracting-investor-140005976.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "ada19761-9639-3856-80e6-30590e3d4902",
      "content": {
        "id": "ada19761-9639-3856-80e6-30590e3d4902",
        "contentType": "STORY",
        "title": "Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know",
        "description": "",
        "summary": "Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
        "pubDate": "2026-02-06T14:00:05Z",
        "displayTime": "2026-02-06T14:00:05Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83",
          "originalWidth": 900,
          "originalHeight": 633,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y5JgUaFZFuBLe5dh5H4ng--~B/aD02MzM7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83.cf.webp",
              "width": 900,
              "height": 633,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IGtpvtZ0OkzJMDD0I3exBg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b369e357aa3d42cc28ac674490d4ae83.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-attracting-investor-140005976.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-jnj-attracting-investor-140005976.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "^GSPC"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-06T14:28:00+00:00",
    "headline": "Low Volatility ETFs to Watch Amid Major Tech Sell-Off Over AI Panic",
    "summary": "USMV and other low-volatility ETFs gain appeal as an AI-driven tech rout wipes $1T, spikes VIX, and fuels rotation into staples and value sectors.",
    "url": "https://finance.yahoo.com/news/low-volatility-etfs-watch-amid-142800832.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "da5ddb44-cde0-31f6-9064-98abdbef0f5f",
      "content": {
        "id": "da5ddb44-cde0-31f6-9064-98abdbef0f5f",
        "contentType": "STORY",
        "title": "Low Volatility ETFs to Watch Amid Major Tech Sell-Off Over AI Panic",
        "description": "",
        "summary": "USMV and other low-volatility ETFs gain appeal as an AI-driven tech rout wipes $1T, spikes VIX, and fuels rotation into staples and value sectors.",
        "pubDate": "2026-02-06T14:28:00Z",
        "displayTime": "2026-02-06T14:28:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/ec93e4a47652cf9206c52a690222a4bc",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nsldjkB1K_SFHVsIPsuFdw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ec93e4a47652cf9206c52a690222a4bc.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VSYOLBAit2H.4TUzzWsjvA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/ec93e4a47652cf9206c52a690222a4bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/low-volatility-etfs-watch-amid-142800832.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/low-volatility-etfs-watch-amid-142800832.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MSFT"
            },
            {
              "symbol": "KO"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "O"
            },
            {
              "symbol": "COR"
            },
            {
              "symbol": "SPLV"
            },
            {
              "symbol": "XOM"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "^VIX"
            },
            {
              "symbol": "CRM"
            },
            {
              "symbol": "NOW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-06T16:04:00+00:00",
    "headline": "Merck's Subdued 2026 Outlook: What it Means After Q4 Results?",
    "summary": "MRK posts conservative 2026 sales and EPS outlook, given acquisition charges. Keytruda, Animal Health and new drug launches are expected to drive 2026 growth.",
    "url": "https://finance.yahoo.com/news/mercks-subdued-2026-outlook-means-160400396.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "2e036f69-4639-3fc5-8744-01a45248ccb7",
      "content": {
        "id": "2e036f69-4639-3fc5-8744-01a45248ccb7",
        "contentType": "STORY",
        "title": "Merck's Subdued 2026 Outlook: What it Means After Q4 Results?",
        "description": "",
        "summary": "MRK posts conservative 2026 sales and EPS outlook, given acquisition charges. Keytruda, Animal Health and new drug launches are expected to drive 2026 growth.",
        "pubDate": "2026-02-06T16:04:00Z",
        "displayTime": "2026-02-06T16:04:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/1b28b8f55ab25205feceb1a2771a2b3a",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RRg0vYpNavphT7S8O9jT7w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1b28b8f55ab25205feceb1a2771a2b3a.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hIkvgr9e5vaptAEV_vkcVg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1b28b8f55ab25205feceb1a2771a2b3a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/mercks-subdued-2026-outlook-means-160400396.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/mercks-subdued-2026-outlook-means-160400396.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "CDTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-06T15:46:00+00:00",
    "headline": "Bayer's Asundexian Shows 26% Stroke Reduction in Late-Stage Study",
    "summary": "Bayer presents positive data on asundexian, which shows superior efficacy with no added bleeding risk, boosting hopes for regulatory approval.",
    "url": "https://finance.yahoo.com/news/bayers-asundexian-shows-26-stroke-154600158.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "4f0ee70c-54cd-380e-b05d-e1510e607a75",
      "content": {
        "id": "4f0ee70c-54cd-380e-b05d-e1510e607a75",
        "contentType": "STORY",
        "title": "Bayer's Asundexian Shows 26% Stroke Reduction in Late-Stage Study",
        "description": "",
        "summary": "Bayer presents positive data on asundexian, which shows superior efficacy with no added bleeding risk, boosting hopes for regulatory approval.",
        "pubDate": "2026-02-06T15:46:00Z",
        "displayTime": "2026-02-06T15:46:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/50c06d1d19c16cb71d6cb49028119372",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5pnU3NQ.800lSpcRBKjZNg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/50c06d1d19c16cb71d6cb49028119372.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/W2_ZZ2Pl7OVNL4tXoICDoQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/50c06d1d19c16cb71d6cb49028119372.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bayers-asundexian-shows-26-stroke-154600158.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bayers-asundexian-shows-26-stroke-154600158.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BAYRY"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "BAYZF"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-06T15:50:02+00:00",
    "headline": "Johnson & Johnson Is a Resilient Blue-Chip Stock and It Just Hit New All-Time Highs",
    "summary": "Johnson & Johnson (JNJ) has a diversified business model that makes it resilient through economic cycles. JNJ is trading at new all-time highs. The stock maintains a 100% “Buy” technical opinion from Barchart. Analyst sentiment is mixed. JNJ has many “Strong Buy” opinions, but some analysts consider JNJ overvalued. Today’s...",
    "url": "https://www.barchart.com/story/news/74008/johnson-johnson-is-a-resilient-blue-chip-stock-and-it-just-hit-new-all-time-highs",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "f463f700-4f45-3042-b488-6bc7c9ae1299",
      "content": {
        "id": "f463f700-4f45-3042-b488-6bc7c9ae1299",
        "contentType": "STORY",
        "title": "Johnson & Johnson Is a Resilient Blue-Chip Stock and It Just Hit New All-Time Highs",
        "description": "",
        "summary": "Johnson & Johnson (JNJ) has a diversified business model that makes it resilient through economic cycles. JNJ is trading at new all-time highs. The stock maintains a 100% “Buy” technical opinion from Barchart. Analyst sentiment is mixed. JNJ has many “Strong Buy” opinions, but some analysts consider JNJ overvalued. Today’s...",
        "pubDate": "2026-02-06T15:50:02Z",
        "displayTime": "2026-02-06T15:50:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/bc531ab7885d2cf67671138eedb42811",
          "originalWidth": 1254,
          "originalHeight": 836,
          "caption": "Johnson & Johnson location sign-by JHVEPhoto via iStock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WxItDWVtCIzt2FJ3UmpHSw--~B/aD04MzY7dz0xMjU0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/barchart_com_477/bc531ab7885d2cf67671138eedb42811.cf.webp",
              "width": 1254,
              "height": 836,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QikPTc9YwcWzMCIsLH.J6Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/bc531ab7885d2cf67671138eedb42811.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/74008/johnson-johnson-is-a-resilient-blue-chip-stock-and-it-just-hit-new-all-time-highs",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-resilient-blue-chip-155002374.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-06T22:06:54+00:00",
    "headline": "Should Johnson & Johnson’s Expanding Oncology Portfolio Alter the Risk Calculus for JNJ Investors?",
    "summary": "Johnson & Johnson recently reported real-world data showing that ERLEADA® without docetaxel was associated with a statistically significant 51% reduction in risk of death versus darolutamide in metastatic castration-sensitive prostate cancer, while also securing FDA approval for DARZALEX FASPRO in combination therapy for newly diagnosed multiple myeloma patients ineligible for stem cell transplant. Together, these oncology advances highlight how Johnson & Johnson is deepening its presence in...",
    "url": "https://finance.yahoo.com/news/johnson-johnson-expanding-oncology-portfolio-220654476.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "27bb0dfc-75ce-3dce-898e-2f2ca5bce12e",
      "content": {
        "id": "27bb0dfc-75ce-3dce-898e-2f2ca5bce12e",
        "contentType": "STORY",
        "title": "Should Johnson & Johnson’s Expanding Oncology Portfolio Alter the Risk Calculus for JNJ Investors?",
        "description": "",
        "summary": "Johnson & Johnson recently reported real-world data showing that ERLEADA® without docetaxel was associated with a statistically significant 51% reduction in risk of death versus darolutamide in metastatic castration-sensitive prostate cancer, while also securing FDA approval for DARZALEX FASPRO in combination therapy for newly diagnosed multiple myeloma patients ineligible for stem cell transplant. Together, these oncology advances highlight how Johnson & Johnson is deepening its presence in...",
        "pubDate": "2026-02-06T22:06:54Z",
        "displayTime": "2026-02-06T22:06:54Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VmOStVnJjLnU3xikg4stLA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/trESudVvS0UypUeXuQ_Yww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4e8319e0e61499a110aef17faa48c1a7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-expanding-oncology-portfolio-220654476.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/johnson-johnson-expanding-oncology-portfolio-220654476.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]